Testing maraviroc to help motor skills recover after stroke
Tests maraviroc against a placebo in adults recovering from ischemic stroke.
Plain-language title generated from the registry record
Registry title: Manipulating the Peri-Infarct Area Using Maraviroc to Enhance Motor Skills After Stroke
Key facts
- Where
- Geneva, SwitzerlandSee the site
- Phase
- Phase 2
Where in Switzerland
- Geneva University HospitalGeneva, SwitzerlandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Emmanuel Carrera
- Trial code
- NCT07080567
- Record updated
- 12 August 2025
- Original description
MASTER is a single-center, patient and investigator-blinded, Randomized Controlled Trial (RCT) to compare the efficacy of Maraviroc, a C-C chemokine receptor 5 (CCR5) antagonist, against placebo regarding motor function and motor learning skills in the first 3 months after ischemic stroke.Read full original descriptionShow less
Maraviroc for Stroke Recovery (MASTER): A Phase 2 Double-Blind Placebo-Controlled Randomized Clinical Trial
MASTER is a single-center, patient and investigator-blinded, Randomized Controlled Trial (RCT) to compare the efficacy of Maraviroc, a C-C chemokine receptor 5 (CCR5) antagonist, against placebo regarding motor function and motor learning skills in the first 3 months after ischemic stroke.
Inclusion: Informed consent as documented by signature; ≥18 years at time of signing of informed consent; Acute ischemic stroke; Stroke onset < 7 days from randomization; Contralateral, unilateral, incomplete upper limb paresis, incl. :; FMA-UE < 63/66; Residual voluntary finger extension (VFE) of > 10 degrees.
Exclusion: Concomitant use of strong CYP3A4 inhibitors or inducers; Pre-stroke handicap (mRS > 2); Diseases affecting motor function (e.g., Parkinson's Disease, Amyotrophic Lateral Sclerosis (ALS)); Known hypersensitivity to Maraviroc, Mannitol, peanuts, or soy; History of significant liver disease, hepatitis, elevated liver function tests (> 1.5 upper limit of normal); HIV infection; History of significant renal disease or End Stage Renal Disease/dialysis, acute renal injury, Creatinine Clearance (CrCl < 30ml/min/1.73m2); Pregnancy/lactation or positive pregnancy test in women of childbearing age; Participation in another study with investigational medicinal product within 30 days preceding and during the present study; Enrolment of the investigator, his/her family members, employees, or other dependent persons; Patients with cardiovascular comorbidities and risk for orthostatic hypotension.